Cargando…

A probability of benefit (AUC) approach to phase II cancer trials

Detalles Bibliográficos
Autor principal:	Silcocks, Paul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4660174/ http://dx.doi.org/10.1186/1745-6215-16-S2-P227

Ejemplares similares

Pragmatic constraint-led approach to sample size
por: Silcocks, Paul, et al.
Publicado: (2015)

Simple tools for projecting patient recruitment
por: Silcocks, Paul
Publicado: (2013)

1090. Does calculation method matter for targeting vancomycin AUC?
por: Chang, Jack, et al.
Publicado: (2021)

Experiences in the design and implementation of phase II trials in CLL
por: Cohen, Dena R, et al.
Publicado: (2011)

AucPR: An AUC-based approach using penalized regression for disease prediction with high-dimensional omics data
por: Yu, Wenbao, et al.
Publicado: (2014)

The importance of planning for a seamless transition in an adaptive phase II randomised trial
por: Marshall, Andrea, et al.
Publicado: (2011)

1107. Vancomycin AUC Dosing: Is One Concentration in the Hand Worth Two in the Bush?
por: Spivey, Justin, et al.
Publicado: (2021)

The Open AUC Project
por: Cölfen, Helmut, et al.
Publicado: (2009)

A discussion of an issue relating to sample sizes of exact phase II trial designs
por: Howman, Andrew
Publicado: (2013)

A phase II randomized trial of doxorubicin (DXR) and gemcitabine (GMZ) administered in patients with metastatic breast cancer (MBC)
por: Bensalem, A, et al.
Publicado: (2005)

A toxicity-dependent feasibility bound for the escalation with overdose control approach in phase I cancer trials
por: Wheeler, Graham, et al.
Publicado: (2015)

1328. Vancomycin exposure and utilization following implementation of an AUC-guided monitoring guideline in children
por: Quraishi, Ruquaya, et al.
Publicado: (2020)

Phase I/II clinical trial of anti-OX40, radiation and cyclophosphamide in patients with prostate cancer: immunological analysis
por: Kovacsovics-Bankowski, Magdalena, et al.
Publicado: (2013)

Analytical Ultracentrifugation (AUC): An Overview of the Application of Fluorescence and Absorbance AUC to the Study of Biological Macromolecules
por: Edwards, Garrett B., et al.
Publicado: (2020)

1310. Implementation of AUC:MIC Pharmacy to Dose in an Academic Medical Center: A Pilot Study
por: Idusuyi, Ann-Marie, et al.
Publicado: (2020)

The use of historical priors to improve the efficiency of phase II clinical trials with time-to-event endpoints
por: Jackson, Richard, et al.
Publicado: (2013)

Correcting AUC for Measurement Error
por: Rosner, Bernard, et al.
Publicado: (2015)

Correcting for selection bias in two-stage trials with multiple correlated outcomes: application to seamless phase ii/iii clinical trials
por: Robertson, David, et al.
Publicado: (2015)

Adaptive designs for phase II cross-over dose-finding trials using Bayesian model averaging
por: Simpson, Sarah, et al.
Publicado: (2015)

Immune correlates in a Phase II clinical trial with ipilimumab in combination with finite androgen deprivation therapy in patients with metastatic non-castrate prostate cancer
por: Subudhi, Sumit K, et al.
Publicado: (2015)

Preliminary results of a triple peptide escalating dose vaccination phase I/II clinical trial as consolidation treatment in women affected by ovarian cancer
por: Napoletano, Chiara, et al.
Publicado: (2013)

Phase II trial designs for complex interventions: a single-arm single-stage design for clustered continuous outcomes
por: Wilson, Duncan T, et al.
Publicado: (2015)

A randomized, double-blind, placebo-controlled, Phase I/II trial of RNActive(®)-vaccine cv9104 in patients with metastatic castrate-refractory prostate cancer (mcrpc): first results of the Phase I part
por: Koch, Sven D, et al.
Publicado: (2014)

Improving phase ii oncology trial using best observed RECIST response as an endpoint by modelling continuous tumour measurements
por: Lin, Chien-Ju, et al.
Publicado: (2015)

Enrolment and logistical challenges in TaMoVac 01 Phase I/II HIV trial despite the completion of an earlier (HIVIS-03 trial trial) in Dar es Salaam
por: Ngatoluwa, M, et al.
Publicado: (2012)

Direct AUC optimization of regulatory motifs
por: Zhu, Lin, et al.
Publicado: (2017)

Benefits and harms of placebo in surgical randomised clinical trials: a systematic review
por: Wartolowska, Karolina, et al.
Publicado: (2013)

Design of Phase II cancer trials evaluating survival probabilities
por: Case, L Douglas, et al.
Publicado: (2003)

1327. Vancomycin Dosing by AUC(24)/MIC in Comparison to Traditional Trough Dosing in Office Infusion Centers (OICs)
por: Luu, Quyen, et al.
Publicado: (2020)

Lentiviral-based anti-HIV therapeutic vaccine: design, preclinical studies and phaseI/II clinical trial preliminary results
por: Bauche, Cécile, et al.
Publicado: (2014)

A phase II study of lenalidomide in patients with relapsed or refractory ATLL
por: Phillips, Adrienne A, et al.
Publicado: (2014)

Demographic and outcome differences in ICU patients with proven invasive candidiasis, possible invasive candidiasis and probable candida colonization: analysis of the EPIC II study population
por: Kett, D, et al.
Publicado: (2011)

Preliminary update of the Mortality Probability Model (MPM0)
por: Higgins, T, et al.
Publicado: (2005)

DPV-001 an autophagosome-enriched cancer vaccine in phase II clinical trials contains 25 putative cancer antigens, DAMPS, HSPS and agonists for TLR 2, 3, 4, 7 and 9
por: Hilton, Traci L, et al.
Publicado: (2013)

Estimating probability of germline mismatch repair mutations in colorectal cancer patients with microsatellite stable tumors
por: Everett, Jessica N, et al.
Publicado: (2011)

Evaluation of a Novel Glucose Area Under the Curve (AUC) Monitoring System: Comparison with the AUC by Continuous Glucose Monitoring
por: Ugi, Satoshi, et al.
Publicado: (2016)

P-047: PROSPECTIVE IDENTIFICATION OF VARIABLES AS OUTCOMES FOR TREATMENT (PIVOT): A PHASE II CLINICAL TRIAL OF HYDROXYUREA FOR CHILDREN AND ADULTS WITH HBSC DISEASE
por: L., SMART, et al.
Publicado: (2022)

Benefits of Synbiotic 2000 Forte in critically ill patients: a randomized controlled trial
por: Voudouris, A, et al.
Publicado: (2005)

35. A referred case of probable PMR with a different outcome
por: Nawaz, Asif, et al.
Publicado: (2019)

Goal-directed therapy in cancer surgery: a randomised and controlled trial (GRICS II)
por: Gerent, A, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_ltpn48690ph5d9s34nk8d95o8f